Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.60 USD
-0.10 (-5.88%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.59 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 21 - 40 ( 122 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Readout Imminent; Data-Rich 2023; Lower PT To $5; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Phase 2 Data & Phase 3 Start for OCU400 in 2023, 2 New INDs in 2Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 2/3 Covaxin Immuno- Bridging Trial Clears A Hurdle
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
FDA OKs NeoCart Phase 3 Design, OCU400 Receives Orphan Drug For RP & LCA
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Highest of Three OCU400 Dose Escalation Doses Selected For Dose Expansion
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Steady Progress in the Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Well Funded to Advance Its Broad Pipeline, 2023 For Clinical Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Partnership with Washington University for COVID-19 Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVID Vaccine Study Rolling; Pipeline Diversified; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Well Funded to Execute its Preclinical and Clinical Pipelines
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Looking Forward to COVAXIN & OCU400 Driving Initial Value, TP of $8/Share
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z